JSPR
Jasper Therapeutics, Inc.
Key Financials
Operating Income
$-83883000
↓ 10.0%
Net Income
$-75801000
↓ 6.4%
Total Assets
$35.8M
↓ 55.2%
Shareholders' Equity
$4.2M
↓ 93.3%
Total Liabilities
$31.6M
↑ 73.5%
Cash & Equivalents
$28.7M
↓ 59.9%
EPS (Diluted)
$-3.95
↑ 19.2%
Operating Cash Flow
$-77161000.00
↓ 23.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/14/2026 | View on SEC |
| 8-K | 5/14/2026 | View on SEC |
| SCHEDULE 13G/A | 5/12/2026 | View on SEC |
| SCHEDULE 13G/A | 5/8/2026 | View on SEC |
| SCHEDULE 13G/A | 5/8/2026 | View on SEC |
| 10-K/A | 4/30/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| SCHEDULE 13G | 2/25/2026 | View on SEC |
| SCHEDULE 13D/A | 2/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | JSPR |
| Company Name | Jasper Therapeutics, Inc. |
| CIK | 1788028 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 6505491400 |